Citadel Advisors
SLS icon

Citadel Advisors’s SELLAS Life Sciences SLS Stock Holding History

Citadel Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.3M Buy
2,258,400
+1,808,600
+402% +$12.5M ﹤0.01% 1981
2026
Q1 		$1.9M Buy
449,800
+353,100
+365% +$1.58M ﹤0.01% 6164
2025
Q4 		$365K Buy
96,700
+31,300
+48% +$60.8K ﹤0.01% 9730
2025
Q3 		$105K Buy
65,400
+32,400
+98% +$57.7K ﹤0.01% 11823
2025
Q2 		$72.3K Buy
33,000
+6,700
+25% +$10.3K ﹤0.01% 11563
2025
Q1 		$28.4K Sell
26,300
-2,400
-8% -$2.85K ﹤0.01% 12872
2024
Q4 		$29.8K Sell
28,700
-46,000
-62% -$52.5K ﹤0.01% 12883
2024
Q3 		$93.4K Buy
74,700
+63,000
+538% +$77K ﹤0.01% 11219
2024
Q2 		$13.9K Buy
11,700
+10,100
+631% +$13.7K ﹤0.01% 12912
2024
Q1 		$1.62K Sell
1,600
-13,700
-90% -$11.5K ﹤0.01% 14108
2023
Q4 		$16.2K Sell
15,300
-1,800
-11% -$1.95K ﹤0.01% 12801
2023
Q3 		$28K Sell
17,100
-7,900
-32% -$12.5K ﹤0.01% 12338
2023
Q2 		$39.3K Sell
25,000
-22,900
-48% -$36.8K ﹤0.01% 12082
2023
Q1 		$68.5K Buy
47,900
+34,200
+250% +$84.6K ﹤0.01% 11769
2022
Q4 		$32.3K Buy
13,700
+3,000
+28% +$8.41K ﹤0.01% 12645
2022
Q3 		$22K Sell
10,700
-100
-0.9% -$276 ﹤0.01% 12039
2022
Q2 		$24K Sell
10,800
-10,600
-50% -$31.1K ﹤0.01% 12326
2022
Q1 		$143K Buy
+21,400
New +$125K ﹤0.01% 11912
2021
Q4 		– Sell
-23,900
Closed -$219K – 14682
2021
Q3 		$219K Sell
23,900
-9,200
-28% -$85.4K ﹤0.01% 11801
2021
Q2 		$367K Buy
33,100
+13,600
+70% +$133K ﹤0.01% 10781
2021
Q1 		$167K Buy
+19,500
New +$160K ﹤0.01% 11931
2018
Q1 		– Sell
-18
Closed -$7K – 8734
2017
Q4 		$7K Buy
18
+6
+50% +$2.9K ﹤0.01% 7904
2017
Q3 		$6K Buy
12
+3
+33% +$1.98K ﹤0.01% 7453
2017
Q2 		$8K Buy
+9
New +$7.83K ﹤0.01% 7382

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's SLS Position: Q2 2026 in Review

Citadel Advisors sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 64,641 shares — an estimated $446K sold.

Citadel Advisors first reported a position in SLS in Q4 2016 and held it in 24 quarters. The position peaked at $505K in Q4 2024. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Citadel Advisors reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 64,641 SELLAS Life Sciences shares in Q2 2026, an estimated $446K.
  • Citadel Advisors first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 24 quarters.
  • Citadel Advisors's SELLAS Life Sciences position peaked at $505K in Q4 2024.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.